within Pharmacolibrary.Drugs.ATC.M;

model M02AA29
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 1 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Esflurbiprofen is the S-enantiomer of flurbiprofen, a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic and anti-inflammatory properties primarily through inhibition of cyclooxygenase (COX) enzymes. Esflurbiprofen has been investigated as a topical agent for musculoskeletal and joint pain, but it is not widely approved as a separate medication in most countries, with its parent racemate (flurbiprofen) being used more commonly.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are not directly available in peer-reviewed literature for esflurbiprofen itself. Estimates below are inferred based on typical topical NSAID characteristics and existing flurbiprofen data.</p><h4>References</h4><ol><li><p>Amemiya, M, et al., &amp; Koga, H (2021). Comparison of tissue pharmacokinetics of esflurbiprofen plaster with flurbiprofen tablets in patients with knee osteoarthritis: A multicenter randomized controlled trial. <i>Biopharmaceutics &amp; drug disposition</i> 42(9) 418â€“426. DOI:<a href=&quot;https://doi.org/10.1002/bdd.2302&quot;>10.1002/bdd.2302</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34529839/&quot;>https://pubmed.ncbi.nlm.nih.gov/34529839</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M02AA29;
